Episode 1 features Marc Lohrmann, Managing Partner of Vesalius Biocapital III, a 120 €M venture capital fund investing in late-stage companies in drug development, medical devices & diagnostics and eHealth / mHealth, across all of Europe. Prior to joining the fund, Marc started eight life sciences companies, worked as an investment manager at one of Europe’s leading corporate VCs and worked with several corporate finance boutiques focused on life sciences M&A transactions.**In this episode, you’ll learn**– How VBC III works as a country-agnostic VC fund and what Marc believes are the main barriers to more funds investing across Europe.– How investors without a natural sciences background can create value in Life Sciences companies and why technical founders often find this type of investor a refreshing element in the board room.– What Marc would love to change about the European VC scene, what’s important to remember when investing across European borders and what’s next for Marc and Vesalius.